Geoffrey von Maltzahn
General Partner @ Flagship Pioneering
Cambridge, United States
Geoffrey von Maltzahn is a Series B investor at Flagship Pioneering in Cambridge focused on Medical and Health Care. Geoffrey von Maltzahn is Co-Founder, Chief Executive Officer, and Director of Tessera Therapeutics, as well as a General Partner at Flagship Pioneering, where he focuses on inventing technologies and starting companies to address global challenges in medicine and environmental sustainability. He is also a co-founder of Sana Biotechnology, IndigoAgriculture, Kaleido Biosciences (NASDAQ:KLDO), Seres Therapeutics (NASDAQ:MCRB), Axcella Health (NASDAQ:AXLA), Generate Biomedicines, and others.Geoffrey currently serves as Chief Executive Officer and Director of Generate Biomedicines, Chief Innovation Officer and Director of Indigo, and Director of Kaleido Biosciences and Sana Biotechnology. He recently served as Chief Executive Officer of Cobalt Biomedicine, which he led from inception to merger with Sana Biotechnology, and as Kaleido’s Chief Executive Officer, where he led the company from inception to launching multiple clinical studies. Geoffrey also served as Chief Executive Officer of Indigo, where he led the development of the company’s technology platform and the discovery of the company’s first commercial products. Previously, Geoffrey was the Chief Technology Officer of Seres Therapeutics, where he led the discovery of SER-109 and built out the company’s discovery platform.Geoffrey has been recognized with numerous patent grants, awards, and publications. He is listed as an inventor on over 200 patent applications and patents, and he has co-authored more than 20 peer-reviewed articles. Geoffrey has received a number of awards and honors, including Bloomberg 50's Ones to Watch; Business Insider’s 30 Biotech Leaders Under 40; Endpoints 20 Biopharma Leaders Under 40; Boston Chamber of Commerce Ten Outstanding Young Leaders; the prestigious Lemelson-MIT Student Prize, awarded to the most innovative students at MIT; the National Inventors Hall of Fame Graduate Student Prize; the Biomedical Engineering Society Graduate Research Award; and the Harvard-MIT Martha Gray Prize. Geoffrey and his inventions have been profiled by Forbes, The Economist, CNN, Scientific American, Bloomberg Businessweek, Popular Science, MIT Technology Review, and other media.Geoffrey was awarded a PhD in biomedical engineering and medical physics from MIT under the mentorship of Sangeeta N. Bhatia, MD, PhD; an MS in bioengineering from the University of California, San Diego; and an SB in chemical engineering from MIT.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Geoffrey von Maltzahn invests in
Stages Geoffrey von Maltzahn invests in
Countries Geoffrey von Maltzahn invests in
Investment Focus
Industry
- Medical 1 (100%)
- Health Care 1 (100%)
- Biotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Generate Biomedicines
|
Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines. | $370M / Series B / Nov 18, 2021 |
Co-Investors
Abu Dhabi Investment Authority
1 deal together
Alaska Permanent Fund
1 deal together
Altitude Life Science Ventures
1 deal together
ARCH Venture Partners
1 deal together
Fidelity
1 deal together
Fidelity
1 deal together
About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and grows first-in-category ventures to transform human health and sustainability. The company accelerates Flagship Pioneering’s advances in biology, engineering, medicine, energy, and beyond. The firm harnesses science and entrepreneurialism to envision alternative futures, beginning withseemingly unreasonable propositions and navigating to transformational outcomes through an evolutionary methodology.Flagship Pioneering combines innovative capacity, entrepreneurial leadership, and professional capital management in a single enterprise that systematically produces first-in-category companies.
Flagship Pioneering Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Geoffrey von Maltzahn
General Partner
|
|||
Hari Pujar
Operating Partner
|
|||
Thomas de Vlaam
Co-Founder FL86
|
|||
Avak Kahvejian
General Partner
|
|||
Bill Johnson
Vice President of Finance
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Geoffrey von Maltzahn invest in?
Geoffrey von Maltzahn invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Geoffrey von Maltzahn last invest?
The most recent investment recorded for Geoffrey von Maltzahn closed in Nov 2021. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
